Near term GHG emission target (GHG)
Date: 13 Feb 2024
Siro Clinpharm, a Clinical Research Organisation supporting trials from Phase II to Phase IV and beyond post-launch of products, is pleased to announce that the organisation’s near-term greenhouse gas (GHG) emissions reduction targets have been approved by the Science Based Targets initiative (SBTi).
The Science Based Targets initiative (SBTi) is a partnership between CDP, World Resources Institute (WRI), the World Wide Fund for Nature (WWF), and the United Nations Global Compact (UN Global Compact) promotes best practices in science based target setting and independently assesses and approves organization’s targets.
Siro Clinpharm applied for its near-term greenhouse gas emission targets to be approved, and SBTi has confirmed that Siro Clinpharm’s science-based targets meet its criteria.
Siro Clinpharm is committed to:
- reduce scope 1 and scope 2 GHG emissions 42% by 2030 from a 2022 base year;
- measure and reduce its scope 3 emissions.
The Science Based Targets initiative (SBTi) has found Siro Clinpharm to be in line with the ambition to limit global temperature increases to 1.5 degree celsius above pre-industrial level. This reconfirms Siro Clinpharm’s commitment to sustainable growth and acknowledges the organization’s ongoing efforts to limit the effects of climate change.